Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell ...

Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-China rights to 3SBio’s SSGJ-707. Pfizer is ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion.

Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival Pfizer’s licensing deal with China’s 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what ...

A big challenge for healthcare giant Pfizer (PFE 1.04%) is going to be replacing revenue from its COVID-19 vaccine this year and beyond. While it has a strong pipeline that can potentially help ...